4DMT plans to continue enrollment at the 1E12 vg/eye in the dose expansion cohort, including in less advanced patients.Clinical activity observed through functional improvements in treated vs untreated control eyes on two microperimetry endpoints: (1) mean retinal sensitivity and (2) number of loci with >7 dB improvement.Clinical activity observed through anatomical measurements of reduced photoreceptor loss in treated vs untreated control eyes on ellipsoid zone area endpoints.4D-125 was well tolerated in all patients treated to-date (n=8), with no dose-limiting toxicities, no serious adverse events and no chronic inflammation.In the last reported quarter, CELU delivered an earnings surprise of 111.54%. Shares of Celularity have plunged 63.1% in the year-to-date period.Įarnings of Celularity beat estimates in three of the last four quarters and missed the mark once, witnessing a surprise of 51.01% on average. During the same period, the loss estimates per share for 2023 have narrowed from $1.04 to $0.97. In the past 60 days, estimates for Celularity’s 2022 loss per share have narrowed from 84 cents to 56 cents. In the last reported quarter, ANGN delivered an earnings surprise of 41.67%. Shares of Angion Biomedica have plunged 70.0% in the year-to-date period.Įarnings of Angion Biomedica beat estimates in three of the last four quarters and missed the mark once, witnessing a surprise of 66.42% on average. During the same period, the loss estimates per share for 2023 have narrowed from $1.54 to $1.43. In the past 60 days, estimates for Angion Biomedica’s 2022 loss per share have narrowed from $1.64 to $1.53. You can see the complete list of today’s Zacks #1 Rank stocks here. Some better-ranked stocks in the overall healthcare sector include Angion Biomedica ANGN, Celularity CELU and Entera Bio ENTX, each sporting a Zacks Rank #1 (Strong Buy) at present. Management also plans to report additional clinical data from all three cohorts of the PRISM study in second-quarter 2023.ĤD Molecular currently carries a Zacks Rank #3 (Hold). This positive interim data also showed that 80% of patients did not require any supplemental aflibercept injections for up to approximately 10 months, thereby remaining anti-VEGF injection-free.īased on data from the PRISM study, 4D Molecular plans to initiate the phase II expansion portion of the PRISM study in first-quarter 2023. Management enrolled participants in the PRISM study who frequently required anti-VEGF injections (i.e., a mean annualized anti-VEGF injection rate of ~11). At a low dose of 3E10 vg/eye, patients who received a single intravitreal injection of 4D-150 experienced a clinically significant reduction in annualized anti-VEGF injection rate by 96.7%. Currently, the company is enrolling study participants in cohort 2 of this phase I/II study.Įarlier this week, 4D Molecular also reported interim data from cohort 1 of the phase I/II PRISM study on intravitreal-administered 4D-150 as a potential treatment for wet AMD. Management intends to report additional data from this study next year. Data from the study showed successful widespread delivery and expression of the 4D-710 CFTRΔR transgene in all samples across all study participants. Last month, FDMT announced interim data from cohort 1 of the phase I/II study evaluating 4D-710 (administered via aerosol delivery) for cystic fibrosis lung disease. This upside was attributed to positive interim data reported by 4D Molecular from its clinical stage studies on its gene-therapy pipeline candidates in cystic fibrosis and wet age-related macular degeneration (wet AMD) indications.
0 kommentar(er)
